FDA Approves ctDNA-Guided Atezolizumab for Bladder Cancer
News Context
At a glance
- Food and Drug Administration has approved the use of IV atezolizumab and atezolizumab with hyaluronidase-tqjs for the treatment of bladder cancer.
- According to reporting from Medscape Medical News on May 15, 2026, the approval is ctDNA-guided.
- This regulatory action marks the first approval for bladder cancer since 2022, when the accelerated approval of atezolizumab for urothelial carcinoma was withdrawn.
The U.S. Food and Drug Administration has approved the use of IV atezolizumab and atezolizumab with hyaluronidase-tqjs for the treatment of bladder cancer.
According to reporting from Medscape Medical News on May 15, 2026, the approval is ctDNA-guided.
This regulatory action marks the first approval for bladder cancer since 2022, when the accelerated approval of atezolizumab for urothelial carcinoma was withdrawn.